Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Bo Didley who wrote (750)	8/16/1999 11:01:00 AM
From: JDN	Read Replies (1) \| Respond to of 5582

dear Dan: I have been away on vacation for past 10 days but doesnt look to me like much has changed in the stock price?? JDN

To: Bo Didley who wrote (750)	8/31/1999 3:02:00 PM
From: Mike M	Read Replies (1) \| Respond to of 5582

I estimate that sales in that range would translate to profits between $1.70 and $2.60 per share. No argument with the possibilities for volume...I would only argue that, even if the revenue is that incredible, it is not likely that Gary will allow the profits to be so high as he goes after market share for Zicam... This, of course, would translate to even better profits a few years down the road.... I believe that surging revenue and modest earnings will be the name of the game for GUMM for the next few years.... Mike